search4answers Posted May 16, 2009 Share Posted May 16, 2009 Asenapine (Saphris) is a new atypical antipsychotic under development for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merge with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA accepted the manufacturer's NDA on November 26, 2007 for standard review.  "Prolactin levels were higher in the risperidone group (79%) than in the asenapine or placebo groups (9% and 2%, respectively). Asenapine-treated patients reported a lower rate of clinically significant weight gain versus risperidone-treated patients (4.3% versus 17%, 1.9% for placebo). " http://www.redorbit.com/news/health/114558...tudy/index.html some hope maybe....? Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.